# US 2025/0145622 A1 · Solid forms of a triazine derivative as cbl-b modulator

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145622 A1
- Document ID: US20250145622A1
- Status: Published application
- Kind: A1
- Application number: 19/016,543
- Filed: 2025-01-10
- Published: 2025-05-08
- Earliest claimed: 2022-07-12
- Assignees: Hotspot Therapeutics, Inc.
- Applicants: Hotspot Therapeutics, Inc.
- Inventors: Jon P. LAWSON; Ken CARSON; Yingzhi BI
- Web page: https://patentgrep.com/patent/US20250145622A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 35/00: Antineoplastic agents
- C07C 59/265: Citric acid
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present disclosure provides, in part, provides crystalline forms of the compound of formula (I). Also provided are pharmaceutical compositions including a crystalline form of the compound of formula (I), as well as methods of treating various condition, diseases, and disorders using the crystalline forms of the compound of formula (I) and pharmaceutical compositions.

## Claims

### Claim 1

A crystalline form of a compound of formula (I):

### Claim 2 (depends on 1)

The crystalline form of claim 1, wherein the crystalline form is a crystalline salt.

### Claim 3 (depends on 1, 2)

The crystalline form of claim 1 or 2, wherein the crystalline form is an unsolvated crystalline form.

### Claim 4 (depends on 1, 2)

The crystalline form of claim 1 or 2, wherein the crystalline form is a crystalline solvate.

### Claim 5

A crystalline form of a compound of formula (I):
wherein the crystalline form is characterized by an X-ray powder diffraction (XRPD) pattern comprising one or more peaks selected from 6.0°±0.2°, 8.6°±0.2°, 14.3°±0.2°, and 16.3°±0.2°2-theta.

### Claim 6 (depends on 5)

The crystalline form of claim 5, wherein the XRPD pattern further comprises one or more peaks selected from 15.6°±0.2°, 17.4°±0.2°, 18.2°±0.2°, 19.9°±0.2°, 20.4°±0.2°, and 21.5°±0.2°2-theta.

### Claim 7 (depends on 5, 6)

The crystalline form of claim 5 or 6, wherein the XRPD pattern further comprises one or more peaks selected from 7.1°±0.2°, 11.7°±0.2°, 12.1°±0.2°, 14.7°±0.2°, 15.1°±0.2°, 18.5°±0.20, 19.6°±0.2°, 20.6°±0.2°, 20.9°±0.2°, 22.0°±0.2°, 22.3°±0.2°, 22.7°±0.2°, 23.00±0.20, 23.2°±0.2°, 24.4°±0.2°, 24.8°±0.2°, 25.2°±0.2°, 25.6°±0.2°, 26.1°±0.2°, 26.40±0.2°, 27.1°±0.2°, 27.5°±0.2°, 28.1°±0.2°, 28.5°±0.2°, 28.7°±0.2°, 29.3°±0.2°, 29.8°±0.2°, and 30.5°±0.2°2-theta.

### Claim 8 (depends on 5, 6, 7)

The crystalline form of any one of claims 5-7, wherein the crystalline form is characterized by an XRPD pattern substantially the same as shown in FIG. 1.

### Claim 9 (depends on 5, 6, 7, 8)

The crystalline form of any one of claims 5-8, wherein the crystalline form exists in an orthorhombic crystal system and has a P212121 space group.

### Claim 10 (depends on 9)

The crystalline form of claim 9, wherein the crystalline form is characterized by the following crystallographic unit cell parameters:
Unit cell dimensions
a = 6.37450(10) Å
α = 90°
b = 18.1063(3) Å
β = 90°
c = 24.8603(4) Å
γ = 90°
Volume
2869.34(8) Å3

### Claim 11 (depends on 5, 6, 7, 8, 9, 10)

The crystalline form of any one of claims 5-10, the crystalline form is characterized by an endotherm with a peak onset of about 165° C. to about 180° C., as determined by differential scanning calorimetry.

### Claim 12 (depends on 5, 6, 7, 8, 9, 10, 11)

The crystalline form of any one of claims 5-11, wherein the crystalline form is an anhydrous crystalline form.

### Claim 13

A crystalline solvate of a compound of formula (I):

### Claim 14 (depends on 13)

The crystalline solvate of claim 13, wherein the crystalline solvate is an acetone solvate, a p-dioxanes solvate, or a tetrahydrofuran solvate.

### Claim 15

A crystalline acetone solvate of a compound of formula (I):

### Claim 16 (depends on 15)

The crystalline acetone solvate of claim 15, wherein the acetone solvate is a mono-acetone solvate.

### Claim 17 (depends on 15, 16)

The crystalline acetone solvate of claim 15 or 16, wherein the crystalline acetone solvate is characterized by an X-ray powder diffraction (XRPD) pattern comprising one or more peaks selected from 6.4°±0.2°, 16.2°±0.2°, 17.2°±0.2°, and 22.0°±0.2°2-theta.

### Claim 18 (depends on 17)

The crystalline acetone solvate of claim 17, wherein the XRPD pattern further comprises one or more peaks selected from 12.0°±0.2°, 14.3°±0.2°, 15.7°±0.2°, 17.8°±0.2°, 20.2°±0.2°, 21.8°±0.2°, and 22.6°±0.2°2-theta.

### Claim 19 (depends on 17, 18)

The crystalline acetone solvate of claim 17 or 18, wherein the XRPD pattern further comprises one or more peaks selected from 7.8°±0.2°, 9.8°±0.2°, 10.4°±0.2°, 12.8°±0.2°, 14.1°±0.2°, 15.1°±0.2°, 17.6°±0.2°, 18.4°±0.2°, 18.6°±0.2°, 19.2°±0.2°, 20.5°±0.20, 21.2°±0.2°, 22.8°±0.2°, 23.3°±0.2°, 23.6°±0.2°, 24.0°±0.2°, 24.3°±0.2°, 24.9°±0.20, 25.0°±0.2°, 25.4°±0.2°, 25.8°±0.2°, 26.1°±0.2°, 26.3°±0.2°, 27.0°±0.2°, 27.7°±0.20, 28.3°±0.2°, 28.7°±0.2°, 29.3°±0.2°, 29.7°±0.2°, 30.1°±0.2°, 30.6°±0.20, and 31.1°±0.20 2-theta.

### Claim 20 (depends on 17, 18, 19)

The crystalline acetone solvate of any one of claims 17-19, wherein the crystalline acetone solvate is characterized by an XRPD pattern substantially the same as shown in FIG. 6.

### Claim 21 (depends on 15, 16, 17, 18, 19, 20)

The crystalline acetone solvate of any one of claims 15-20, wherein the crystalline acetone solvate exists in an orthorhombic crystal system and has a P212121 space group.

### Claim 22 (depends on 21)

The crystalline acetone solvate of claim 21, wherein the crystalline acetone solvate is characterized by the following crystallographic unit cell parameters:
Unit cell dimensions
a = 6.251 Å
α = 90°
b = 15.082 Å
β = 90°
c = 33.920 Å
γ = 90°
Volume
3197.9 Å3

### Claim 23 (depends on 15, 16, 17, 18, 19, 20, 21, 22)

The crystalline acetone solvate of any one of claims 15-22, wherein the crystalline acetone solvate is characterized by one or more endotherms with peak maxima selected from about 100° C., about 107° C., and about 173° C., as determined by differential scanning calorimetry.

### Claim 24

A crystalline p-dioxane solvate of a compound of formula (I):

### Claim 25 (depends on 24)

The crystalline p-dioxane solvate of claim 24, wherein the p-dioxane solvate is a mono-p-dioxane solvate.

### Claim 26 (depends on 24, 25)

The crystalline p-dioxane solvate of claim 24 or 25, wherein the crystalline p-dioxane solvate is characterized by an X-ray powder diffraction (XRPD) pattern comprising one or more peaks selected from 6.3°±0.2°, 16.0°±0.2°, 17.0°±0.2°, and 21.8°±0.2°2-theta.

### Claim 27 (depends on 26)

The crystalline p-dioxane solvate of claim 26, wherein the XRPD pattern further comprises one or more peaks selected from 11.8°±0.2°, 14.2°±0.2°, 17.5°±0.2°, 20.0°±0.2°, and 21.6°±0.2°2-theta.

### Claim 28 (depends on 26, 27)

The crystalline p-dioxane solvate of claim 26 or 27, wherein the XRPD pattern further comprises one or more peaks selected from 5.2°, 0.2°, 7.7°±0.2°, 10.3°±0.2°, 12.6°±0.2° 14.9°±0.2°, 15.4°±0.2°, 15.5°±0.2°, 18.1°±0.2°, 18.4°±0.2°, 18.9°±0.2°, 19.1°±0.20, 19.4°±0.2°, 20.2°±0.2°, 21.0°±0.2°, 22.4°±0.2°, 23.0°±0.2°, 23.1°±0.2°, 23.8°±0.20, 24.0°±0.2°, 24.7°±0.2°, 25.2°±0.2°, 25.4°±0.2°, 25.8°±0.2°, 27.3°±0.2°, 27.8°±0.20, 28.0°±0.2°, 28.3°±0.2°, and 28.9°±0.2°2-theta.

### Claim 29 (depends on 26, 27, 28)

The crystalline p-dioxane solvate of any one of claims 26-28, wherein the crystalline p-dioxane solvate is characterized by an XRPD pattern substantially the same as shown in FIG. 10.

### Claim 30 (depends on 24, 25, 26, 27, 28, 29)

The crystalline p-dioxane solvate of any one of claims 24-29, wherein the crystalline p-dioxane solvate exists in an orthorhombic crystal system and has a P212121 space group.

### Claim 31 (depends on 30)

The crystalline p-dioxane solvate of claim 30, wherein the crystalline p-dioxane solvate is characterized by the following crystallographic unit cell parameters:
Unit cell dimensions
a = 6.316 Å
α = 90°
b = 15.364 Å
β = 90°
c = 34.166 Å
γ = 90°
Volume
3315.4 Å3

### Claim 32 (depends on 24, 25, 26, 27, 28, 29, 30, 31)

The crystalline p-dioxane solvate of any one of claims 24-31, wherein the crystalline p-dioxane solvate is characterized by an endotherm with a peak onset of about 94° C., as determined by differential scanning calorimetry.

### Claim 33

A crystalline tetrahydrofuran solvate of a compound of formula (I):

### Claim 34 (depends on 33)

The crystalline tetrahydrofuran solvate of claim 33, wherein the tetrahydrofuran solvate is a mono-tetrahydrofuran solvate.

### Claim 35 (depends on 33, 34)

The crystalline tetrahydrofuran solvate of claim 33 or 34, wherein the crystalline tetrahydrofuran solvate is characterized by an X-ray powder diffraction (XRPD) pattern comprising one or more peaks selected from 6.3°±0.2°, 16.1°±0.2°, 17.3°±0.2°, and 22.9°±0.2°2-theta.

### Claim 36 (depends on 35)

The crystalline tetrahydrofuran solvate of claim 35, wherein the XRPD pattern further comprises one or more peaks selected from 17.1°±0.2°, 17.9°±0.2°, and 22.4°±0.2°2-theta.

### Claim 37 (depends on 35, 36)

The crystalline tetrahydrofuran solvate of claim 35 or 36, wherein the XRPD pattern further comprises one or more peaks selected from 7.7°±0.2°, 11.4°±0.2°, 11.7°±0.2°, 11.9°±0.2°, 12.5°±0.2°, 14.3°±0.2°, 15.2°±0.2°, 15.5°±0.2°, 18.3°±0.2°, 18.9°±0.2°, 19.8°±0.2°, 20.1°±0.2°, 21.0°±0.2°, 21.7°±0.2°, 21.9°±0.2°, 23.5°±0.2°, 24.1°±0.2°, 24.6°±0.2°, 25.3°±0.2°, 25.9°±0.2°, 27.1°±0.2°, 27.3°±0.2°, 28.4°±0.2°, 28.9°±0.2°, 29.5°±0.2°, 30.0°±0.2°, and 30.8°±0.2°2-theta.

### Claim 38 (depends on 35, 36, 37)

The crystalline tetrahydrofuran solvate of any one of claims 35-37, wherein the crystalline tetrahydrofuran solvate is characterized by an XRPD pattern substantially the same as shown in FIG. 14.

### Claim 39 (depends on 33, 34, 35, 36, 37, 38)

The crystalline tetrahydrofuran solvate of any one of claims 33-38, wherein the crystalline tetrahydrofuran solvate exists in an orthorhombic crystal system and has a P212121 space group.

### Claim 40 (depends on 39)

The crystalline tetrahydrofuran solvate of claim 39, wherein the crystalline tetrahydrofuran solvate is characterized by the following crystallographic unit cell parameters:
Unit cell dimensions
a = 6.289 Å
α = 90°
b = 15.515 Å
β = 90°
c = 33.823 Å
γ = 90°
Volume
3300.2 Å3

### Claim 41 (depends on 33, 34, 35, 36, 37, 38, 39, 40)

The crystalline tetrahydrofuran solvate of any one of claims 33-40, wherein the crystalline tetrahydrofuran solvate is characterized by an endotherm with a peak onset of about 85° C., as determined by differential scanning calorimetry.

### Claim 42

A crystalline citrate salt of a compound of formula (I):

### Claim 43 (depends on 42)

The crystalline citrate salt of claim 42, wherein the crystalline citrate salt is characterized by an X-ray powder diffraction (XRPD) pattern comprising one or more peaks selected from 5.0±0.2°, 6.6±0.2, 17.6±0.2°, and 18.2±0.2°2-theta.

### Claim 44 (depends on 43)

The crystalline citrate salt of claim 43, wherein the XRPD pattern further comprises one or more peaks selected from 15.°±0.2°, 15.3±0.2°, 16.9±0.2, 19.7±0.2, 20.1±0.2°, 22.6±0.2°, 22.8±0.2°, and 24.8±0.2°2-theta.

### Claim 45 (depends on 43, 44)

The crystalline citrate salt of claim 43 or 44, wherein the XRPD pattern further comprises one or more peaks selected from 8.6±0.2, 10.°±0.2°, 11.°±0.2, 11.5±0.2°, 13.2±0.2, 13.3±0.2°, 14.6±0.2°, 15.9±0.2°, 16.3±0.2°, 16.5±0.2°, 21.0 0.2°, 21.5±0.2°, 21.8±0.2°, 23.2±0.2°, 23.4±0.2°, 23.9±0.2°, 24.6±0.2°, 25.2±0.2°, 26.°±0.2°, 26.6±0.2°, 27.3±0.2°, 28.9±0.2°, 29.5±0.2, 29.8±0.2, and 30.4±0.2°2-theta.

### Claim 46 (depends on 43, 44, 45)

The crystalline citrate salt of any one of claims 43-45, wherein the crystalline citrate salt is characterized by an XRPD pattern substantially the same as shown in FIG. 18.

### Claim 47 (depends on 42, 43, 44, 45, 46)

The crystalline citrate salt of any one of claims 42-46, wherein the crystalline citrate salt exists in an orthorhombic crystal system and has a P212121 space group.

### Claim 48 (depends on 47)

The crystalline citrate salt of claim 47, wherein the crystalline citrate salt is characterized by the following crystallographic unit cell parameters:
Unit cell dimensions
a = 6.150 Å
α = 90°
b = 20.489 Å
β = 90°
c = 34.845 Å
γ = 90°
Volume
4390.7 Å3

### Claim 49 (depends on 42, 43, 44, 45, 46, 47, 48)

The crystalline citrate salt of any one of claims 42-48, wherein the crystalline citrate salt is characterized by an endotherm with a peak onset of about 110° C., as determined by differential scanning calorimetry.

### Claim 50 (depends on 42, 43, 44, 45, 46, 47, 48, 49)

The crystalline citrate salt of any one of claims 42-49, wherein the crystalline citrate salt is an acetone solvated crystalline citrate salt.

### Claim 51 (depends on 42)

The crystalline citrate salt of claim 42, wherein the crystalline citrate salt is characterized by an XRPD pattern comprising one or more peaks selected from 5.1±0.2°, 6.9±0.2, 17.8±0.2°, and 18.7±0.2°2-theta.

### Claim 52 (depends on 51)

The crystalline citrate salt of claim 51, wherein the XRPD pattern further comprises one or more peaks selected from 17.2±0.2°, 22.3±0.2°, 23.3±0.2, and 23.6±0.2°2-theta.

### Claim 53 (depends on 51, 52)

The crystalline citrate salt of claim 51 or 52, wherein the XRPD pattern further comprises one or more peaks selected from 5.4±0.2°, 8.6±0.2°, 9.2±0.2°, 10.1±0.2°, 10.8±0.2°, 11.7±0.2°, 13.2±0.2°, 13.9±0.2°, 14.0 0.2°, 14.8±0.2°, 15.2±0.2°, 15.4±0.2°, 16.1±0.2°, 16.9±0.2°, 17.4±0.2°, 18.°±0.2°, 19.1±0.2°, 19.5±0.2°, 19.7±0.2°, 19.9±0.2°, 20.2±0.2°, 20.4±0.2°, 20.9±0.2°, 21.1±0.2°, 21.8±0.2°, 21.9±0.2°, 22.6±0.2°, 22.8±0.2°, 23.8±0.2°, 24.1±0.2°, 24.4±0.2, 25.2±0.2°, 25.5±0.2°, 26.°±0.2°, 26.5±0.2°, 26.7±0.2°, 27.4±0.2, 27.9±0.2, 28.4±0.2°2-theta.

### Claim 54 (depends on 51, 52, 53)

The crystalline citrate salt of any one of claims 51-53, wherein the crystalline citrate salt is characterized by an XRPD pattern substantially the same as shown in FIG. 22.

### Claim 55 (depends on 42, 51, 52, 53, 54)

The crystalline citrate salt of any one of claims 42 and 51-54, wherein the crystalline citrate salt exists in an orthorhombic crystal system and has a P212121 space group.

### Claim 56 (depends on 55)

The crystalline citrate salt of claim 55, wherein the crystalline citrate salt is characterized by the following crystallographic unit cell parameters:
Unit cell dimensions
a = 6.081 Å
α = 90°
b = 20.605 Å
β = 90°
c = 32.628 Å
γ = 90°
Volume
4088.3 Å3

### Claim 57 (depends on 42, 51, 52, 53, 54, 55, 56)

The crystalline citrate salt of any one of claims 42 and 51-56, wherein the crystalline citrate salt is an acetonitrile solvated crystalline citrate salt.

### Claim 58 (depends on 42)

The crystalline citrate salt of claim 42, wherein the crystalline citrate salt is characterized by an XRPD pattern comprising one or more peaks selected from 5.3±0.2°, 6.4±0.2, 17.6±0.2°, and 23.°±0.2°2-theta.

### Claim 59 (depends on 58)

The crystalline citrate salt of claim 58, wherein the XRPD pattern further comprises one or more peaks selected from 8.5±0.2°, 10.6±0.2°, 16.°±0.2, 17.°±0.2, 17.3±0.2°, 18.2±0.2°, 21.4±0.2°, and 22.4±0.2°2-theta.

### Claim 60 (depends on 58, 59)

The crystalline citrate salt of claim 58 or 59, wherein the XRPD pattern further comprises one or more peaks selected from 7.6±0.2, 9.1±0.2, 12.8±0.2°, 14.4±0.2°, 15.4±0.2, 16.4±0.2°, 16.7±0.2°, 19.°±0.2°, 19.3±0.2°, 19.5±0.2°, 20.1±0.2°, 20.9±0.2°, 24.3±0.2°, 25.7±0.2, 25.8±0.2, 26.4±0.2°, 27.4±0.2°, and 28.°±0.2°2-theta.

### Claim 61 (depends on 58, 59, 60)

The crystalline citrate salt of any one of claims 58-60, wherein the crystalline citrate salt is characterized by an XRPD pattern substantially the same as shown in FIG. 24.

### Claim 62 (depends on 42, 58, 59, 60, 61)

The crystalline citrate salt of any one of claims 42 and 58-61, wherein the crystalline citrate salt exists in an orthorhombic crystal system and has a P212121 space group.

### Claim 63 (depends on 62)

The crystalline citrate salt of claim 62, wherein the crystalline citrate salt is characterized by the following crystallographic unit cell parameters:
Unit cell dimensions
a = 6.297 Å
α = 90°
b = 20.855 Å
β = 90°
c = 27.665 Å
γ = 90°
Volume
3633.1 Å3

### Claim 64 (depends on 42, 58, 59, 60, 61, 62, 63)

The crystalline citrate salt of any one of claims 42 and 58-63, wherein the crystalline citrate salt is characterized by an endotherm with a peak maximum of about 131° C., as determined by differential scanning calorimetry.

### Claim 65 (depends on 42, 58, 59, 60, 61, 62, 63, 64)

The crystalline citrate salt of any one of claims 42 and 58-64, wherein the crystalline citrate salt is an anhydrous citrate salt.

### Claim 66 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The crystalline citrate salt of any one of claims 42-65, wherein the citrate salt is a mono-citrate salt.

### Claim 67 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

A pharmaceutical composition comprising:
the crystalline form of any one of claims 1-12, the crystalline solvate of any one of claims 13-41, or the crystalline citrate salt of any one of claims 42-66; and
a pharmaceutically acceptable excipient.

### Claim 68 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

A method of treating a disease or condition associated with cell proliferation comprising administering a therapeutically effective amount of a crystalline form of any one of claims 1-12, a crystalline solvate of any one of claims 13-41, a crystalline citrate salt of any one of claims 42-66, or a pharmaceutical composition of claim 67 to a subject in need thereof.

### Claim 69 (depends on 68)

The method of claim 68, wherein the disease or condition associated with cell proliferation is hyperplasia or a cancer.

### Claim 70 (depends on 69)

The method of claim 69, wherein the cancer is a hematologic cancer.

### Claim 71 (depends on 70)

The method of claim 70, wherein the hematologic cancer is selected from a group consisting of a lymphoma, a leukemia, and a myeloma.

### Claim 72 (depends on 69)

The method of claim 69, wherein the cancer is a non-hematologic cancer.

### Claim 73 (depends on 72)

The method of claim 72, wherein the non-hematologic cancer is a sarcoma or a carcinoma.

### Claim 74 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73)

The method of any one of claims 68-73, wherein the subject has one or more of increased T-cell activation, increased T-cell proliferation, decreased T-cell exhaustion, decreased T-cell anergy, and decreased T-cell tolerance after administration of a crystalline form of any one of claims 1-12, a crystalline solvate of any one of claims 13-41, a crystalline citrate salt of any one of claims 42-66, or a pharmaceutical composition of claim 67.

### Claim 75 (depends on 74)

The method of claim 74, wherein increased T-cell activation comprises increased production of a cytokines.

### Claim 76 (depends on 68, 69, 70, 71, 72, 73)

The method of any one of claims 68-73, wherein the subject has increased NK-cell activation.
